

OBN BioTuesday: ‘What’s happening in



Image
Coming
Soon

Start Date: Tuesday, November 21, 2017

5:30 PM

End Date: Tuesday, November 21, 2017 9:00 PM

We are pleased to announce details of a Special Edition OBN BioTuesday event, providing an overview and update from the industry on: ‘What’s happening in Cancer?’

Our high-level speakers will give an update on the latest innovative technologies and breakthroughs in cancer therapies by scientists and R&D companies in the Oxford area. They will also provide an overview of how the latest drug discoveries are being funded, focusing on the move towards collaboration between academia and big pharma to help accelerate the discovery process and introduce ground-breaking treatments into a clinical setting far sooner than ever before.

The event is kindly co-hosted by Ipsen and Immunocore and is being held at the Ipsen Bioinnovation on Milton Park, Oxford, which is the UK R&D Centre for Ipsen on Tuesday 21st November.

About our hosts:

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumours, renal cell carcinoma and pancreatic cancer.

Immunocore is the world’s leading T cell receptor (TCR) company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, through its pioneering soluble TCR technology platform. The scientific expertise at Immunocore spans the entire process of drug development. From the discovery and validation of suitable disease targets, through to the design and engineering of immune-activating TCR-based reagents, and preclinical and clinical assessment.

Agenda:

17:30 Registration and networking

18:00 Welcome and introductions from Dr John Harris, CEO of OBN (UK), Dr John Chaddock, Vice